Dossier assessment
Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Added benefit not proven for pretreated or treatment-naive patients
Press releases
Melanoma: dabrafenib and trametinib have added benefit
Additional information
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.
Project details
- Project no.
- A18-61
- Commission
- Commission awarded on 27.09.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed